Antibody drug conjugates (ADC) that bind to CD37 proteins

US11633500B2 · kind B2 · utility

Assignee

• Latency, LLC · US

Inventors

• Daniel Pereira · Los Angeles, US
• Faisal Hayat Malik · Cerritos, US
• Josh SNYDER · Santa Monica, US
• Leslie Renee Butterworth · Kirkland, US
• Ssucheng Jeff Hsu · Pinole, US
• Peng Yang · Tainan, TW
• Claudia Isabel Guevara · South Gate, US

Key dates

• Filing date: Apr 17, 2020
• Grant date: Apr 25, 2023
• Expiry date: Dec 28, 2040

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P35/02
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Antibody drug conjugates (ADC's) that bind to CD37 protein and variants thereof are described herein. CD37 exhibits a distinct and limited expression pattern in normal adult tissue(s), and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention in some embodiments provide a therapeutic composition for the treatment of cancer.